Germany Pioneers Compassionate Psilocybin Access for Treatment-Resistant Depression in EU First

Germany is now the first EU country to allow psilocybin therapy under compassionate use for TRD patients unable to access clinical trials. Filament Health is central to Germany’s landmark initiative, bringing a natural, GMP-grade psilocybin drug to patients most in need, at no cost, while enabling a safe and streamlined path to treatment.